TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29420324

Group type: EXPERIMENTAL
Intervention: Preoperative mitomycin C (MMC) injection (0.1 mL of 0.15 mg/mL MMC) followed by pterygium excision and conjunctival autograft (CAG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intraoperative local application of MMC (0.2 mg/mL for 2 min) over the medial rectus tendon followed by pterygium excision and CAG
Number of subjects: 108
Study: 27281308

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 744
Study: 24731467

Group type: EXPERIMENTAL
Intervention: Soy protein containing 70 mg isoflavone daily for one year
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group without soy protein intake
Number of subjects: 75
Study: 21962771

Group type: COMPARATOR
Intervention: Oral intervention (O)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tactile/Kinesthetic intervention (T/K)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Combined intervention (O+T/K)
Number of subjects: 75

Group type: COMPARATOR
Intervention: All three interventions (O, T/K, O+T/K)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 75
Study: 21911634

Group type: EXPERIMENTAL
Intervention: Nonaspirin NSAIDs
Number of subjects: 126928

Group type: COMPARATOR
Intervention: Aspirin and acetaminophen
Number of subjects: 126928
Study: 18187944

Group type: EXPERIMENTAL
Intervention: PASI 100
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: PASI 90 to <100
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: PASI 75 to <90
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: PASI 50 to <75
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: PASI 25 to <50
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: PASI <25
Number of subjects: 1469
Study: 16638934

Group type: EXPERIMENTAL
Intervention: Concurrent imatinib and induction cycle 2 (INDII)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Alternating imatinib schedule
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Concurrent imatinib and chemotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 92
Study: 14719287

Group type: EXPERIMENTAL
Intervention: Bufei Keli (Chinese drug granules for invigorating the lung)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Yupingfeng Keli (control group)
Number of subjects: 62
Study: 10771454

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg day‐1 in two divided daily doses for 8 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8658373

Group type: EXPERIMENTAL
Intervention: Thiorphan 1 mg (in 2 ml) followed by ANP 5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: ANP 5 mg alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (saline) followed by ANP 5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Salbutamol 5 mg
Number of subjects: 6
Study: 1804493

Group type: EXPERIMENTAL
Intervention: SK&F 104353‐Z2 (800 micrograms via aerosol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SK&F 104353‐Z2
Number of subjects: 12
Study: 6095658

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30739640

Group type: EXPERIMENTAL
Intervention: Single 2.0-mm AO locking reconstruction plate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Two conventional miniplates
Number of subjects: 80
Study: 30552161

Group type: EXPERIMENTAL
Intervention: Obinutuzumab preinduction (2 cycles)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induction I (6 cycles obinutuzumab and venetoclax)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induction II (6 cycles venetoclax)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maintenance with 12 additional cycles of venetoclax irrespective of MRD (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MRD guided venetoclax maintenance with a maximum of 12 cycles (group B)
Number of subjects: 30
Study: 27074873

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Poor effort group
Number of subjects: 60
Study: 24930624

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1090

Group type: COMPARATOR
Intervention: IFN‐α/Placebo
Number of subjects: 1090
Study: 22964703

Group type: EXPERIMENTAL
Intervention: Dexpantenolo (pantothenic acid derivative), administered intravenously during the second and third post-operative day.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiological solution (Placebo), administered to the control group.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spinal anesthetic treatment group.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peridural anesthetic treatment group.
Number of subjects: 60
Study: 20645106

Group type: COMPARATOR
Intervention: Atenolol (25 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Higher CVR
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lower CVR
Number of subjects: 67
Study: 17949673

Group type: EXPERIMENTAL
Intervention: Ranibizumab (LUCENTIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verteporfin (VISUDYNE) photodynamic therapy (PDT)
Number of subjects: 0
Study: 15827560

Group type: EXPERIMENTAL
Intervention: 80:20 CLA isomer blend (1.76 g CLA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CLA (2 g CLA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Linoleic acid (2 g linoleic acid)
Number of subjects: 55
Study: 12107508

Group type: EXPERIMENTAL
Intervention: 0.5% timolol eyedrops
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous timolol (0.2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ocular timolol (0.2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ophthalmic timolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous timolol
Number of subjects: 8
Study: 9661686

Group type: EXPERIMENTAL
Intervention: Preoperative blood deposit status (autologous blood collection)
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Transfusion(s) received
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Mean number of units collected per patient
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Mean number of unused autologous units per 100 patients
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Deposited blood requiring allogeneic units
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 2590

Group type: EXPERIMENTAL
Intervention: Last hematocrits
Number of subjects: 2590
Study: 7697521

Group type: EXPERIMENTAL
Intervention: Francisella tularensis live vaccine strain (LVS)
Number of subjects: 0
Study: 2653095

Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 1.5% with adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural fentanyl (100 micrograms in saline 10 ml)
Number of subjects: 40
Study: 331052

Group type: EXPERIMENTAL
Intervention: Methadyl acetate (80 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methadone (50 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methadone (100 mg)
Number of subjects: 60
Study: 31917441

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab, 0.5 mg, in a Treat-and-Extend (T&E) regimen
Number of subjects: 580

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab, 0.5 mg, in monthly dosing regimen
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: T&E regimen
Number of subjects: 580

Group type: COMPARATOR
Intervention: Monthly regimen
Number of subjects: 580
Study: 29459994

Group type: EXPERIMENTAL
Intervention: Diode laser enucleation of the prostate (DiLEP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bipolar endoscopic enucleation of the prostate (BEEP)
Number of subjects: 114
Study: 28394249

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic psychotherapy (STPP)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Brief psychosocial intervention (BPI)
Number of subjects: 465
Study: 25778541

Group type: EXPERIMENTAL
Intervention: Grape/blueberry juice (841 mg ACN/litre)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Grape/blueberry smoothie (983 mg ACN/litre)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Grape/blueberry juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Grape/blueberry smoothie
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: In vitro absorption of grape/blueberry extract
Number of subjects: 10
Study: 24337060

Group type: EXPERIMENTAL
Intervention: Online version of the Female Sexual Function Index (FSFI)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Traditional pen and paper version of the FSFI
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Online version of the FSFI (G-pp/ol after 15 days)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Traditional pen and paper version of the FSFI (G-ol/pp after 15 days)
Number of subjects: 273
Study: 20543220

Group type: EXPERIMENTAL
Intervention: Standardized rehabilitation protocol with physiotherapists trained in a clinical rehabilitation model
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standardized rehabilitation protocol without self-efficacy scores provided to physiotherapists
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clinical rehabilitation model with strategies to enhance self-efficacy
Number of subjects: 40
Study: 18753292

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg infusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 22
Study: 16551930

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 36
Study: 14556729

Group type: EXPERIMENTAL
Intervention: Hydrofibre(R) dressing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Glycerol preserved allograft skin
Number of subjects: 80
Study: 10917403

Group type: EXPERIMENTAL
Intervention: 20 mg FLX daily
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 60 mg FLX weekly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 8645377

Group type: EXPERIMENTAL
Intervention: Chronic maternal cocaine use (MCU+) with positive neonatal urine cocaine test (NUC+)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Chronic maternal cocaine use (MCU+) with negative neonatal urine cocaine test (NUC-)
Number of subjects: 87

Group type: COMPARATOR
Intervention: No chronic maternal cocaine use (MCU-) and negative neonatal urine cocaine test (NUC-)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Holter monitor assessment
Number of subjects: 87
Study: 1626677

Group type: EXPERIMENTAL
Intervention: Low-dose morphine combined with bupivacaine for intercostal nerve blocks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine alone (control)
Number of subjects: 0
Study: 6386330

Group type: EXPERIMENTAL
Intervention: Disulfiram treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no disulfiram, told they are not receiving disulfiram)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (given disulfiram, told they are receiving disulfiram)
Number of subjects: 0
Study: 31793645

Group type: EXPERIMENTAL
Intervention: Nutrivida (fortified food)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nutrisano (fortified food)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Syrup (alternative supplement for children)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MNP-C (micronutrient powders for children)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MNP-W (micronutrient powders for women)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Any supplement (general outcome)
Number of subjects: 54
Study: 29195851

Group type: EXPERIMENTAL
Intervention: Posterior referencing (PR) system
Number of subjects: 211

Group type: COMPARATOR
Intervention: Anterior referencing (AR) system
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study: 26649466

Group type: EXPERIMENTAL
Intervention: Cue exposure intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study: 24499750

Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling
Number of subjects: 130

Group type: COMPARATOR
Intervention: Transobturator sling
Number of subjects: 130
Study: 22609816

Group type: EXPERIMENTAL
Intervention: Sertindole (modal dose 16 mg/day)
Number of subjects: 294
Study: 20555277

Group type: EXPERIMENTAL
Intervention: Standing long jump (SLJ)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Other lower body muscular strength tests (vertical jump, squat jump, countermovement jump)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Upper body muscular strength tests (throw basketball, push-ups, isometric strength exercises)
Number of subjects: 94
Study: 17437689

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 0
Study: 15758010

Group type: EXPERIMENTAL
Intervention: Temozolomide and radiotherapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 206
Study: 12098155

Group type: EXPERIMENTAL
Intervention: Robot-assisted movement training (24 sessions of 1 hour over 2 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional therapy techniques (neurodevelopmental therapy with 5 minutes of robot exposure per session)
Number of subjects: 27
Study: 10081851

Group type: EXPERIMENTAL
Intervention: Single immediate instillation of 30 mg mitomycin C
Number of subjects: 131

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 131
Study: 7569360

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 198

Group type: COMPARATOR
Intervention: Animal insulin
Number of subjects: 198
Study: 2287773

Group type: EXPERIMENTAL
Intervention: Once-a-day amikacin (14 mg/kg per day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Once-a-day netilmicin (6.6 mg/kg per day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional schedule amikacin (cs)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional schedule netilmicin (cs)
Number of subjects: 78
Study: 6795047

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (1,25(OH)2D3) alone in a daily dose of 0.25 micrograms
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oestrogens/gestagen alone or combined with 1,25(OH)2D3
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 29893798

Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg once daily)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 28487415

Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapeutic pharmaceutical protocols (Control)
Number of subjects: 0
Study: 26377909

Group type: EXPERIMENTAL
Intervention: 40% dextrose gel (200 mg/kg)
Number of subjects: 2129

Group type: COMPARATOR
Intervention: 2% hydroxymethylcellulose placebo
Number of subjects: 2129
Study: 23587733

Group type: EXPERIMENTAL
Intervention: teduglutide (0.05 mg/kg/day s.c.)
Number of subjects: 86

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study: 21863254

Group type: EXPERIMENTAL
Intervention: First eye surgery under topical anesthesia
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Second eye surgery under topical anesthesia
Number of subjects: 73

Group type: COMPARATOR
Intervention: First eye surgery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Second eye surgery
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Correlation between VAS scores of first and second procedures
Number of subjects: 73
Study: 18987127

Group type: EXPERIMENTAL
Intervention: Esmolol titrated to achieve a heart rate of <100 bpm followed by ibutilide (IB) co-administration
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ibutilide (IB) as monotherapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Esmolol and IB combination therapy
Number of subjects: 90
Study: 17287476

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus placebo
Number of subjects: 626

Group type: COMPARATOR
Intervention: Extended-release metformin plus placebo
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Combination of metformin and clomiphene
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 626

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 626
Study: 15377967

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) users
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Non-menstruating OCP users
Number of subjects: 127
Study: 11216737

Group type: EXPERIMENTAL
Intervention: Minimally invasive direct coronary artery bypass grafting (MIDCABG)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Beating heart surgery
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard CABG
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study: 9474310

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anaesthesia
Number of subjects: 129

Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 129
Study: 7959185

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol (a selective beta 1 antagonist)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched dummy tablets (control)
Number of subjects: 10
Study: 3610510

Group type: EXPERIMENTAL
Intervention: Benzydamine (0.3% concentration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Similar solution without the active substance (Control)
Number of subjects: 40
Study: 28927636

Group type: EXPERIMENTAL
Intervention: Upstream dual anti-platelet therapy (DAT) with aspirin and clopidogrel without intra-procedural anti-coagulation (Group 1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Upstream dual anti-platelet therapy (DAT) with aspirin and clopidogrel plus intra-procedural bivalirudin (Group 2)
Number of subjects: 200
Study: 26874946

Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg, three times daily from 2 days before to 3 days after procedure)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (matching placebo)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 23644602

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenges
Number of subjects: 191

Group type: COMPARATOR
Intervention: No L. brevis lozenge (control)
Number of subjects: 191
Study: 23529727

Group type: EXPERIMENTAL
Intervention: fast-release GSK1322322
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GSK1322322 with high-fat meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GSK1322322 with H2 blocker
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GSK1322322 with H2 blocker plus vitamin C
Number of subjects: 20
Study: 19923796

Group type: EXPERIMENTAL
Intervention: GLY-230 (250, 500, or 750 mg daily for 14 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GLY-230
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 18248644

Group type: COMPARATOR
Intervention: Oral 17-beta-oestradiol (E(2)) 1, 2 and 4 mg daily in a cyclical formulation for 12 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Oral contraceptive pill (OCP)
Number of subjects: 125
Study: 16758262

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg once daily for 5 days)
Number of subjects: 10
Study: 14558184

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 8677

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 8677

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 8677

Group type: EXPERIMENTAL
Intervention: Concomitant use of medication contra-indicated in the drugs' labeling
Number of subjects: 8677

Group type: EXPERIMENTAL
Intervention: Increasing number of other concomitant medications
Number of subjects: 8677

Group type: EXPERIMENTAL
Intervention: History of previous GI disorder
Number of subjects: 8677

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 8677

Group type: EXPERIMENTAL
Intervention: Ibuprofen vs Paracetamol for GI SAE
Number of subjects: 8677
Study: 11352967

Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 9424602

Group type: EXPERIMENTAL
Intervention: rt-PA (recombinant plasminogen activator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8199751

Group type: EXPERIMENTAL
Intervention: 10 mg pantoprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg pantoprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 80 mg pantoprazole
Number of subjects: 12
Study: 2439833

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Aprotinin infusion
Number of subjects: 17
Study: 31921328

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding counselling based on Carl Rogers' Centred‐Client Theory, performed during the last month of pregnancy, 24 hours after delivery, and during early infancy (1 and 3 months postpartum).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard management (control group).
Number of subjects: 0
Study: 29206274

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention programme (n = 141)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Belief that work was cause of the pain
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Anxiety and depression
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Interaction between multidisciplinary intervention and perceived support at work
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Duration of sick leave
Number of subjects: 284
Study: 28389864

Group type: EXPERIMENTAL
Intervention: FIFA 11+ injury prevention program
Number of subjects: 136